Page Loader Image
  • About Us
  • Knowledge Hub
  • Resources
  • Events
  • In the media
  • Contact
Public Pharma For Europe
Public Pharma For Europe
Public Pharma For Europe
  • About Us
  • Knowledge Hub
  • Resources
  • Events
  • In the media
  • Contact
Public Pharma For Europe
  • About Us
  • Knowledge Hub
  • Resources
  • Events
  • In the media
  • Contact

‘HIV-ending’ drug could be made for just $25 per patient a year, say researchers

Author: The Guardian

Date:  6/17/25

Language: English

Learn More: https://www.theguardian.com/society/2025/jun/17/hiv-ending-drug-lenacapavir-manufacture-cost-per-patient-gilead

You might also enjoy

La política del medicamento en la UE y su renuncia a la salud global

Read More »

The European Pharmaceutical Package Agreement: an insufficient step that preserves industry privileges and fails to guarantee equitable access to medicines

Read More »

New $55 Insulin Pens Mark Step in California’s Fight Against Insulin Price Gouging

Read More »

The UK must defend drug price controls

Read More »

The pandemic accord: new possibilities for public health industrialisation pathways?

Read More »

Greed Is a Hell of a Drug

Read More »